Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Votan2015on Mar 29, 2020 10:13am

72 Views

Post# 30857269

RE:RE:Every retail investor should read the article posted by

Votan2015 wrote:
edrose wrote: Skl6600 written by our cso pugiv who works for kly and stero and and I think talent who’s friends with bassada
article in Europa health
they even have arrogance to put in writing at end of article “kly recently acquired stero dated March 27th 2020 WE DIDNT EVEN VOTE AND SHE’S SPREADING FALSE INFORMATION IN WRITING.

I would keep her accountable and deliver Stero to Kly without any payment as we didn't pay for it. So according to her we got Stero for free, Hurray!!

And she stated it as the part of Stero managment with her title beside.

Bullboard Posts

Changing Europe’s dependency on HREE from China